Q1 Earnings Estimate for CNTB Issued By HC Wainwright

Key Points

• HC Wainwright projects Q1 2026 EPS of ($0.24) and FY2026 EPS of ($0.98), with estimates improving to $0.02 by FY2030.
• Director James Huang bought 1,160,000 shares at $3.45 on March 31, raising his holdings to 13,160,000 shares (a 9.67% increase); insiders now own 22.6% of the stock.
• Shares opened at $2.78 (trading up 5.7%), the company has a market cap of about $157M, and analysts give a consensus Moderate Buy with an average target of $8.67.

Connect Biopharma Holdings Limited Sponsored ADR (NASDAQ:CNTB - Free Report) - Stock analysts at HC Wainwright issued their Q1 2026 earnings estimates for shares of Connect Biopharma in a research note issued on Wednesday, April 8th. HC Wainwright analyst B. Folkes expects that the company will post earnings of ($0.24) per share for the quarter. The consensus estimate for Connect Biopharma's current full-year earnings is ($0.22) per share. HC Wainwright also issued estimates for Connect Biopharma's Q2 2026 earnings at ($0.24) EPS, Q3 2026 earnings at ($0.24) EPS, Q4 2026 earnings at ($0.26) EPS, FY2026 earnings at ($0.98) EPS, FY2027 earnings at ($0.92) EPS, FY2028 earnings at ($0.71) EPS, FY2029 earnings at ($0.42) EPS and FY2030 earnings at $0.02 EPS.

Other equities research analysts have also recently issued research reports about the stock. Weiss Ratings reissued a "sell (d-)" rating on shares of Connect Biopharma in a report on Wednesday, January 21st. Wall Street Zen raised shares of Connect Biopharma to a "hold" rating in a report on Saturday, December 20th. Finally, BTIG Research reaffirmed a "buy" rating and issued a $10.00 price target on shares of Connect Biopharma in a report on Tuesday, March 31st. One investment analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $8.67.

Connect Biopharma Trading Up 5.7%

Shares of CNTB stock opened at $2.78 on Friday. The company's fifty day simple moving average is $2.73 and its two-hundred day simple moving average is $2.36. The company has a debt-to-equity ratio of 0.01, a current ratio of 3.74 and a quick ratio of 3.74. Connect Biopharma has a 1 year low of $0.60 and a 1 year high of $3.82. The stock has a market capitalization of $157.13 million, a price-to-earnings ratio of -2.78 and a beta of -0.21.

Connect Biopharma (NASDAQ:CNTB - Get Free Report) last issued its earnings results on Tuesday, March 31st. The company reported ($0.27) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.30) by $0.03. The business had revenue of ($0.05) million for the quarter, compared to the consensus estimate of $0.00 million.

Insider Buying and Selling at Connect Biopharma

In other news, Director James Huang purchased 1,160,000 shares of the firm's stock in a transaction dated Tuesday, March 31st. The shares were purchased at an average price of $3.45 per share, with a total value of $4,002,000.00. Following the completion of the acquisition, the director owned 13,160,000 shares in the company, valued at $45,402,000. This trade represents a 9.67% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this hyperlink. Insiders own 22.60% of the company's stock.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the company. Perceptive Advisors LLC bought a new position in shares of Connect Biopharma in the fourth quarter worth $2,235,000. Knott David M Jr purchased a new position in Connect Biopharma in the fourth quarter worth $564,000. Richmond Brothers Inc. purchased a new position in Connect Biopharma in the fourth quarter worth $489,000. Marshall Wace LLP grew its position in Connect Biopharma by 121.2% in the fourth quarter. Marshall Wace LLP now owns 128,368 shares of the company's stock worth $362,000 after acquiring an additional 70,337 shares in the last quarter. Finally, Jane Street Group LLC purchased a new position in Connect Biopharma in the fourth quarter worth $232,000. Institutional investors own 58.72% of the company's stock.

Connect Biopharma Company Profile

Connect Biopharma Holdings Ltd. is a clinical-stage biopharmaceutical company focused on the discovery and development of monoclonal antibody therapies for immune-mediated disorders. Headquartered in Singapore with a research and commercial presence in the United States, the company applies proprietary technology platforms to target novel pathways in inflammatory and autoimmune diseases.

The company's lead product candidate, CBP-201, is a fully human monoclonal antibody that antagonizes the interleukin-31 receptor, a key mediator of chronic pruritus in conditions such as atopic dermatitis and prurigo nodularis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.